期刊文献+

缬沙坦联合丹参注射液对糖尿病肾病患者微量尿白蛋白及血清C反应蛋白的影响 被引量:7

The study of urinary albumin excretion and serum C-reactive protein on patients with diabetic nephropathy treated by Valsartan combined with Salvia injection
下载PDF
导出
摘要 目的观察缬沙坦联合丹参注射液治疗早期糖尿病肾病(DN)的疗效。方法将212例DN患者随机分为对照组和治疗组,对照组102例,给予缬沙坦80mg/d;治疗组110例,在缬沙坦治疗的基础上给予丹参注射液20ml静脉滴注,每日1次,2周为1个疗程。每3个月给予1个疗程的治疗,共治疗18个月。观察治疗前后尿白蛋白排出量(UAE)和血清C反应蛋白(CRP)水平的变化。结果2组治疗后UAE均下降(P〈0.05,P〈0.01),且组间比较差异有显著性(P〈0.01)。疗程结束后,治疗组血清CRP降低(P〈0.01)。对照组降低不明显(P〉0.05),组间比较差异有显著性(P〈0.01)。结论缬沙坦与丹参注射液联合应用可减少UAE、降低血清CRP水平,对早期糖尿病肾病有较好的肾脏保护作用。 Objective To investigate the effect of Valsartan combined with Salvia Injection on the early Diabetic Nephropathy(DN). Method 212 patients with DN were randomly divided into two groups: the control group and the treatment group. 102 patients in control group received Valsartan 80mg/per day, while 110 patients in treatment group received additional 20 ml Salvia Injection by intravenous injection. Both of two groups were treated for 18 months, once a day,two weeks for one course and one course every three months. The changes of Urinary Albumin Excretion( UAE )and serum C-reactive protein(CRP) level were observed before and after theraphy. Results After the treatment, the UAE of the both groups wasdecreased ( P 〈 0.05, P 〈 0.01 ) and there was significant difference ( P 〈 0.01 ) between two groups. The C RP in the treatment group decreased(P 〈0.01 ) ,while there was no change in the control group(P 〉0.05). Significant difference between the two groups was found ( P 〈 0.01 ). Conclusion Valsartan combined with Salvia Injection can reduce UAE and CRP level and has protective effects against early diabetic nephropathy.
出处 《临床内科杂志》 CAS 2010年第2期91-93,共3页 Journal of Clinical Internal Medicine
关键词 糖尿病肾病 微量尿白蛋白 C反应蛋白 丹参注射液 缬沙坦 Diabetic nephropathy Urinary albumin excretion C-reactive protein Salvia injection Valsartan
  • 相关文献

参考文献8

二级参考文献46

  • 1钱浩,吴永贵,林辉,赵珉,周典,郝丽,张伯科.霉酚酸酯对糖尿病大鼠肾组织单核细胞趋化蛋白-1与细胞间黏附分子-1表达的影响[J].中华肾脏病杂志,2004,20(5):375-376. 被引量:9
  • 2李秀钧,邬云红.糖尿病是一种炎症性疾病?[J].中华内分泌代谢杂志,2003,19(4):251-253. 被引量:254
  • 3Pickup JC,Crook MA.Is type Ⅱ diabetes mellitus a disease of the innate immune system?.Diabetologia,1998,41:1241-1248.
  • 4Barzilay JI,Abraham L,Heckbert SR,et al.The relation of markers of inflammtion to the development of glucose disorders in the elderly:the Cardiovascular Health Study.Diabetes,2001,50:2384-2389.
  • 5Aronson D,Bartha P,Zinder O,et al.Association between fasting glucose and C-reactive protein in middle-aged subjects.Diabet Med,2004,21:39-44.
  • 6Saraheimo M,Teppo AM,Forsblom C,et al.Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients.Diabetologia,2003,46:1402-1407.
  • 7Senatorski G,Paczek L,Kropiewnicka E,et al.Cytokines in noninvasive diagnostics of diabetic nephropathy progression.Pol Merkuriusz Lek,2002,13 Suppl 1;28-32.
  • 8Guler S, Cakir B, Demirbas B, et al. Plasma soluble intercellular adhesion molecule 1 levels are increased in type 2 diabetic patients with nephropathy. Horm Res,2002,58:67 - 70.
  • 9Saraheimo M, Teppo AM, Forsblom C, et al. Diabetic nephropathy is associated with low - grade inflammation in Type 1 diabetic patients. Diabetologia, 2003,46:1402 - 7.
  • 10Banba N, Nakamura T, Matsumura M, et al. Possible relationship of monocyte chemoattractant protein - 1 with diabetic nephropathy. Kidney Int,2000,58:684 - 690.

共引文献123

同被引文献87

引证文献7

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部